[en] Thiamine (vitamin B1) is essential for brain function because of the coenzyme role of thiamine diphosphate (ThDP) in glucose and energy metabolism. In order to compensate thiamine deficiency, several thiamine precursors with higher bioavailability were developed since the 1950s. Among these, the thioester benfotiamine (BFT) has been extensively studied and has beneficial effects both in rodent models of neurodegeneration and in human clinical studies. BFT has antioxi- dant and anti-inflammatory properties that seem to be mediated by a mechanism independent of the coenzyme function of ThDP. BFT has no adverse effects and improves cognitive outcome in patients with mild Alzheimer’s disease (AD). Recent in vitro studies show that another thiamine thioester, dibenzoylthiamine (DBT) is even more efficient that BFT, especially with respect to its anti-inflammatory potency. Thiamine thioesters have pleiotropic properties linked to an increase in circulating thiamine concentrations and possibly in hitherto unidentified metabolites in particular open thiazole ring derivatives. The identification of the active neuroprotective derivatives and the clarification of their mechanism of action open extremely promising perspectives in the field of neurodegenerative, neurodevelopmental and psychiatric conditions.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Jansen, B.C.P.; Donath, W.F. On the Isolation of Anti-Beriberi Vitamin. Proc. Kon. Ned. Akad. Wet. 1926, 29, 1390–1400.
Grijns, G. Over Polyneuritis Gallinarum. I. Geneesk Tijdscht Ned. Ind. 1901, 41, 3–110.
Peters, R.A. The Biochemical Lesion in Vitamin B1 Deficiency. Application of Modern Biochemical Analysis in Its Diagnosis. Lancet 1936, 1, 1161–1164. [CrossRef]
Lohmann, K.; Schuster, P. Untersuchungen Über Die Cocarboxylase. Biochem. Z. 1937, 294, 188.
McCandless, D.W. Thiamine Deficiency and Associated Clinical Disorders. In Contemporary Clinical Neuroscience, 1st ed.; Humana Press: Totowa, NJ, USA, 2010.
Page, M.G.; Ankoma-Sey, V.; Coulson, W.F.; Bender, D.A. Brain Glutamate and Gamma-Aminobutyrate (GABA) Metabolism in Thiamin-Deficient Rats. Br. J. Nutr. 1989, 62, 245–253. [CrossRef] [PubMed]
Plaitakis, A.; Hwang, E.C.; Woert, M.H.; Szilagyi, P.E.; Berl, S. Effect of Thiamin Deficiency on Brain Neurotransmitter Systems. Ann. N. Y. Acad. Sci. 1982, 378, 367–381. [CrossRef] [PubMed]
Bettendorff, L. Basic Nutrition and Metabolism. In Present Knowledge in Nutrition, 11th ed.; Marriott, B., Birt, D.F., Stalling, V., Yates, A., Eds.; Academic Press: Cambridge, MA, USA, 2020; Volume 1, p. 676, ISBN 978-0-323-66162-1.
Whitfield, K.C.; Bourassa, M.W.; Adamolekun, B.; Bergeron, G.; Bettendorff, L.; Brown, K.H.; Cox, L.; Fattal-Valevski, A.; Fischer, P.R.; Frank, E.L.; et al. Thiamine Deficiency Disorders: Diagnosis, Prevalence, and a Roadmap for Global Control Programs. Ann N. Y. Acad. Sci. 2018, 1430, 3–43. [CrossRef] [PubMed]
Smith, T.J.; Johnson, C.R.; Koshy, R.; Hess, S.Y.; Qureshi, U.A.; Mynak, M.L.; Fischer, P.R. Thiamine Deficiency Disorders: A Clinical Perspective. Ann. N. Y. Acad. Sci. 2020. [CrossRef]
Calingasan, N.Y.; Chun, W.J.; Park, L.C.; Uchida, K.; Gibson, G.E. Oxidative Stress Is Associated with Region-Specific Neuronal Death during Thiamine Deficiency. J. Neuropathol. Exp. Neurol. 1999, 58, 946–958. [CrossRef]
Karuppagounder, S.S.; Shi, Q.; Xu, H.; Gibson, G.E. Changes in Inflammatory Processes Associated with Selective Vulnerability Following Mild Impairment of Oxidative Metabolism. Neurobiol. Dis. 2007, 26, 353–362. [CrossRef]
Hazell, A.S.; Faim, S.; Wertheimer, G.; Silva, V.R.; Marques, C.S. The Impact of Oxidative Stress in Thiamine Deficiency: A Multifactorial Targeting Issue. Neurochem. Int. 2013, 62, 796–802. [CrossRef] [PubMed]
Gibson, G.E.; Hirsch, J.A.; Fonzetti, P.; Jordan, B.D.; Cirio, R.T.; Elder, J. Vitamin B1 (Thiamine) and Dementia. Ann. N. Y. Acad. Sci. 2016, 1367, 21–30. [CrossRef]
Chandrakumar, A.; Bhardwaj, A.; W’t Jong, G. Review of Thiamine Deficiency Disorders: Wernicke Encephalopathy and Korsakoff Psychosis. J. Basic Clin. Physiol. Pharmacol. 2018, 30, 153–162. [CrossRef]
Bettendorff, L. Thiamine in Excitable Tissues: Reflections on a Non-Cofactor Role. Metab. Brain Dis. 1994, 9, 183–209. [CrossRef]
Bettendorff, L.; Wins, P. Thiamin Diphosphate in Biological Chemistry: New Aspects of Thiamin Metabolism, Especially Triphosphate Derivatives Acting Other than as Cofactors. FEBS J. 2009, 276, 2917–2925. [CrossRef] [PubMed]
Aleshin, V.A.; Mkrtchyan, G.V.; Bunik, V.I. Mechanisms of Non-Coenzyme Action of Thiamine: Protein Targets and Medical Significance. Biochem. Biokhimiia 2019, 84, 829–850. [CrossRef] [PubMed]
Said, H.M. Intestinal Absorption of Water-Soluble Vitamins in Health and Disease. Biochem. J. 2011, 437, 357–372. [CrossRef] [PubMed]
Greenwood, J.; Love, E.R.; Pratt, O.E. Kinetics of Thiamine Transport across the Blood-Brain Barrier in the Rat. J. Physiol. 1982, 327, 95–103. [CrossRef] [PubMed]
Lonsdale, D. A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives. Evid. Based Complementary Altern. Med. 2006, 3, 49–59. [CrossRef]
Starling-Soares, B.; Carrera-Bastos, P.; Bettendorff, L. Role of the Synthetic B1 Vitamin Sulbutiamine on Health. J. Nutr. Metab. 2020, 2020, 9349063. [CrossRef]
Lonsdale, D.; Shamberger, R.J.; Audhya, T. Treatment of Autism Spectrum Children with Thiamine Tetrahydrofurfuryl Disulfide: A Pilot Study. Neuroendocr. Lett. 2002, 23, 303–308.
Hammes, H.P.; Du, X.; Edelstein, D.; Taguchi, T.; Matsumura, T.; Ju, Q.; Lin, J.; Bierhaus, A.; Nawroth, P.; Hannak, D.; et al. Benfotiamine Blocks Three Major Pathways of Hyperglycemic Damage and Prevents Experimental Diabetic Retinopathy. Nat. Med. 2003, 9, 294–299. [CrossRef]
Pan, X.; Gong, N.; Zhao, J.; Yu, Z.; Gu, F.; Chen, J.; Sun, X.; Zhao, L.; Yu, M.; Xu, Z.; et al. Powerful Beneficial Effects of Benfotiamine on Cognitive Impairment and Beta-Amyloid Deposition in Amyloid Precursor Protein/Presenilin-1 Transgenic Mice. Brain 2010, 133, 1342–1351. [CrossRef] [PubMed]
Tapias, V.; Jainuddin, S.; Ahuja, M.; Stack, C.; Elipenahli, C.; Vignisse, J.; Gerges, M.; Starkova, N.; Xu, H.; Starkov, A.A.; et al. Benfotiamine Treatment Activates the Nrf2/ARE Pathway and Is Neuroprotective in a Transgenic Mouse Model of Tauopathy. Hum. Mol. Genet. 2018, 27, 2874–2892. [CrossRef] [PubMed]
Gibson, G.E.; Luchsinger, J.A.; Cirio, R.; Chen, H.; Franchino-Elder, J.; Hirsch, J.A.; Bettendorff, L.; Chen, Z.; Flowers, S.; Gerber, L.; et al. Benfotiamine and Cognitive Decline in Alzheimer’s Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. J. Alzheimers Dis. JAD 2020, 78, 989–1010. [CrossRef] [PubMed]
Pan, X.; Chen, Z.; Fei, G.; Pan, S.; Bao, W.; Ren, S.; Guan, Y.; Zhong, C. Long-Term Cognitive Improvement after Benfotiamine Administration in Patients with Alzheimer’s Disease. Neurosci. Bull. 2016, 32, 591–596. [CrossRef]
Sambon, M.; Gorlova, A.; Demelenne, A.; Alhama-Riba, J.; Coumans, B.; Lakaye, B.; Wins, P.; Fillet, M.; Anthony, D.C.; Strekalova, T.; et al. Dibenzoylthiamine Has Powerful Antioxidant and Anti-Inflammatory Properties in Cultured Cells and in Mouse Models of Stress and Neurodegeneration. Biomedicines 2020, 8, 361. [CrossRef]
Loew, D. Pharmacokinetics of Thiamine Derivatives Especially of Benfotiamine. Int. J. Clin. Pharmacol. Ther. 1996, 34, 47–50.
Lonsdale, D. Benfotiamine and Allithiamine Should Be Differentiated. Townsend Lett. Dr. Patients 2004, 257, 102.
Fujiwara, M.; Watanabe, H.; Katsui, K. Allithiamine, a Newly Found Derivative of Vitamin B1. J. Biochem. 1954, 41, 29–39. [CrossRef]
Sambon, M.; Napp, A.; Demelenne, A.; Vignisse, J.; Wins, P.; Fillet, M.; Bettendorff, L. Thiamine and Benfotiamine Protect Neuroblastoma Cells against Paraquat and β-Amyloid Toxicity by a Coenzyme-Independent Mechanism. Heliyon 2019, 5, e01710. [CrossRef]
Sheng, L.; Cao, W.; Lin, P.; Chen, W.; Xu, H.; Zhong, C.; Yuan, F.; Chen, H.; Li, H.; Liu, C.; et al. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects. Drug Des. Devel. Ther. 2021, 15, 1101–1110. [CrossRef] [PubMed]
Bitsch, R.; Wolf, M.; Moller, J.; Heuzeroth, L.; Gruneklee, D. Bioavailability Assessment of the Lipophilic Benfotiamine as Compared to a Water-Soluble Thiamin Derivative. Ann. Nutr. Metab. 1991, 35, 292–296. [CrossRef]
Gangolf, M.; Czerniecki, J.; Radermecker, M.; Detry, O.; Nisolle, M.; Jouan, C.; Martin, D.; Chantraine, F.; Lakaye, B.; Wins, P.; et al. Thiamine Status in Humans and Content of Phosphorylated Thiamine Derivatives in Biopsies and Cultured Cells. PLoS ONE 2010, 5, e13616. [CrossRef] [PubMed]
Kim, J.; Jonus, H.C.; Zastre, J.A.; Bartlett, M.G. Development of an IPRP-LC-MS/MS Method to Determine the Fate of Intracellular Thiamine in Cancer Cells. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 2019, 1124, 247–255. [CrossRef]
Jonus, H.C.; Byrnes, C.C.; Kim, J.; Valle, M.L.; Bartlett, M.G.; Said, H.M.; Zastre, J.A. Thiamine Mimetics Sulbutiamine and Benfotiamine as a Nutraceutical Approach to Anticancer Therapy. Biomed. Pharm. Biomed. Pharm. 2020, 121, 109648. [CrossRef] [PubMed]
Duclos, J.M.; Haake, P. Ring Opening of Thiamine Analogs. The Role of Ring Opening in Physiological Function. Biochemistry 1974, 13, 5358–5362. [CrossRef]
Hurt, J.K.; Coleman, J.L.; Fitzpatrick, B.J.; Taylor-Blake, B.; Bridges, A.S.; Vihko, P.; Zylka, M.J. Prostatic Acid Phosphatase Is Required for the Antinociceptive Effects of Thiamine and Benfotiamine. PLoS ONE 2012, 7, e48562. [CrossRef]
Volvert, M.L.; Seyen, S.; Piette, M.; Evrard, B.; Gangolf, M.; Plumier, J.C.; Bettendorff, L. Benfotiamine, a Synthetic S-Acyl Thiamine Derivative, Has Different Mechanisms of Action and a Different Pharmacological Profile than Lipid-Soluble Thiamine Disulfide Derivatives. BMC Pharmacol. 2008, 8, 10. [CrossRef]
de Moraes, R.C.M.; Singulani, M.P.; de Gonçalves, A.C.; Portari, G.V.; da Silva Torrão, A. Oral Benfotiamine Reverts Cognitive Deficit and Increase Thiamine Diphosphate Levels in the Brain of a Rat Model of Neurodegeneration. Exp. Gerontol. 2020, 141, 111097. [CrossRef]
Voskoboyev, A.I.; Ostrovsky, Y.M. Thiamin Pyrophosphokinase: Structure, Properties, and Role in Thiamin Metabolism. Ann. N. Y. Acad. Sci. 1982, 378, 161–176. [CrossRef] [PubMed]
Thornalley, P.J. The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications. Curr. Diabetes Rev. 2005, 1, 287–298. [CrossRef]
Woodgett, J.R. Molecular Cloning and Expression of Glycogen Synthase Kinase-3/Factor A. EMBO J. 1990, 9, 2431–2438. [CrossRef] [PubMed]
Perez-Costas, E.; Gandy, J.C.; Melendez-Ferro, M.; Roberts, R.C.; Bijur, G.N. Light and Electron Microscopy Study of Glycogen Synthase Kinase-3beta in the Mouse Brain. PLoS ONE 2010, 5, e8911. [CrossRef]
Peineau, S.; Taghibiglou, C.; Bradley, C.; Wong, T.P.; Liu, L.; Lu, J.; Lo, E.; Wu, D.; Saule, E.; Bouschet, T.; et al. LTP Inhibits LTD in the Hippocampus via Regulation of GSK3beta. Neuron 2007, 53, 703–717. [CrossRef]
Pardo, M.; Abrial, E.; Jope, R.S.; Beurel, E. GSK3β Isoform-Selective Regulation of Depression, Memory and Hippocampal Cell Proliferation. Genes Brain Behav. 2016, 15, 348–355. [CrossRef]
Cross, D.A.; Alessi, D.R.; Cohen, P.; Andjelkovich, M.; Hemmings, B.A. Inhibition of Glycogen Synthase Kinase-3 by Insulin Mediated by Protein Kinase B. Nature 1995, 378, 785–789. [CrossRef]
Beaulieu, J.-M.; Gainetdinov, R.R.; Caron, M.G. Akt/GSK3 Signaling in the Action of Psychotropic Drugs. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 327–347. [CrossRef]
Hooper, C.; Killick, R.; Lovestone, S. The GSK3 Hypothesis of Alzheimer’s Disease. J. Neurochem. 2008, 104, 1433–1439. [CrossRef] [PubMed]
Takashima, A. GSK-3 Is Essential in the Pathogenesis of Alzheimer’s Disease. J. Alzheimers Dis. 2006, 9, 309–317. [CrossRef] [PubMed]
Rockenstein, E.; Torrance, M.; Adame, A.; Mante, M.; Bar-on, P.; Rose, J.B.; Crews, L.; Masliah, E. Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3beta Signaling Pathway in a Transgenic Model of Alzheimer’s Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation. J. Neurosci. Off. J. Soc. Neurosci. 2007, 27, 1981–1991. [CrossRef]
Ly, P.T.T.; Wu, Y.; Zou, H.; Wang, R.; Zhou, W.; Kinoshita, A.; Zhang, M.; Yang, Y.; Cai, F.; Woodgett, J.; et al. Inhibition of GSK3β-Mediated BACE1 Expression Reduces Alzheimer-Associated Phenotypes. J. Clin. Investig. 2013, 123, 224–235. [CrossRef]
Kuhla, A.; Ludwig, S.C.; Kuhla, B.; Münch, G.; Vollmar, B. Advanced Glycation End Products Are Mitogenic Signals and Trigger Cell Cycle Reentry of Neurons in Alzheimer’s Disease Brain. Neurobiol. Aging 2015, 36, 753–761. [CrossRef]
Tebay, L.E.; Robertson, H.; Durant, S.T.; Vitale, S.R.; Penning, T.M.; Dinkova-Kostova, A.T.; Hayes, J.D. Mechanisms of Activation of the Transcription Factor Nrf2 by Redox Stressors, Nutrient Cues, and Energy Status and the Pathways through Which It Attenuates Degenerative Disease. Free Radic. Biol. Med. 2015, 88, 108–146. [CrossRef]
Bozic, I.; Savic, D.; Stevanovic, I.; Pekovic, S.; Nedeljkovic, N.; Lavrnja, I. Benfotiamine Upregulates Antioxidative System in Activated BV-2 Microglia Cells. Front. Cell. Neurosci. 2015, 9, 351. [CrossRef]
Hansen, D.V.; Hanson, J.E.; Sheng, M. Microglia in Alzheimer’s Disease. J. Cell Biol. 2018, 217, 459–472. [CrossRef]
Hazell, A.S.; Butterworth, R.F. Update of Cell Damage Mechanisms in Thiamine Deficiency: Focus on Oxidative Stress, Excitotox-icity and Inflammation. Alcohol. Alcohol. 2009, 44, 141–147. [CrossRef]
Todd, K.G.; Butterworth, R.F. Early Microglial Response in Experimental Thiamine Deficiency: An Immunohistochemical Analysis. Glia 1999, 25, 190–198. [CrossRef]
Sanchez-Ramirez, G.M.; Caram-Salas, N.L.; Rocha-Gonzalez, H.I.; Vidal-Cantu, G.C.; Medina-Santillan, R.; Reyes-Garcia, G.; Granados-Soto, V. Benfotiamine Relieves Inflammatory and Neuropathic Pain in Rats. Eur. J. Pharmacol. 2006, 530, 48–53. [CrossRef] [PubMed]
Yadav, U.C.S.; Kalariya, N.M.; Srivastava, S.K.; Ramana, K.V. Protective Role of Benfotiamine, a Fat-Soluble Vitamin B1 Analogue, in Lipopolysaccharide-Induced Cytotoxic Signals in Murine Macrophages. Free Radic. Biol. Med. 2010, 48, 1423–1434. [CrossRef] [PubMed]
Shoeb, M.; Ramana, K.V. Anti-Inflammatory Effects of Benfotiamine Are Mediated through the Regulation of the Arachidonic Acid Pathway in Macrophages. Free Radic. Biol. Med. 2012, 52, 182–190. [CrossRef]
Vatsalya, V.; Li, F.; Frimodig, J.; Gala, K.S.; Srivastava, S.; Kong, M.; Ramchandani, V.A.; Feng, W.; Zhang, X.; McClain, C.J. Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile. Front. Pharmacol. 2021, 11, 598128. [CrossRef]
Clayton, D.A.; Grosshans, D.R.; Browning, M.D. Aging and Surface Expression of Hippocampal NMDA Receptors. J. Biol. Chem. 2002, 277, 14367–14369. [CrossRef]
Heywood, R.; Wood, J.D.; Majeed, S.K. Tumorigenic and Toxic Effect of O,S-Dibenzoyl Thiamine Hydrochloride in Prolonged Dietary Administration to Rats. Toxicol. Lett. 1985, 26, 53–58. [CrossRef]
Ketola, H.G.; Isaacs, G.R.; Robins, J.S.; Lloyd, R.C. Effectiveness and Retention of Thiamine and Its Analogs Administered to Steelhead and Landlocked Atlantic Salmon. J. Aquat. Anim. Health 2008, 20, 29–38. [CrossRef]
Safavi, M.; Hosseini-Sharifabad, A.; Seyed-Yousefi, Y.; Rabbani, M. Protective Effects of Citicoline and Benfotiamine Each Alone and in Combination on Streptozotocin-Induced Memory Impairment in Mice. Clin. Psychopharmacol. Neurosci. Off. Sci. J. Korean Coll. Neuropsychopharmacol. 2020, 18, 81–92. [CrossRef]
Putnam, E.E.; Goodman, A.L. B Vitamin Acquisition by Gut Commensal Bacteria. PLoS Pathog. 2020, 16, e1008208. [CrossRef] [PubMed]
Costliow, Z.A.; Degnan, P.H. Thiamine Acquisition Strategies Impact Metabolism and Competition in the Gut Microbe Bacteroides Thetaiotaomicron. mSystems 2017, 2. [CrossRef] [PubMed]
Fung, T.C.; Olson, C.A.; Hsiao, E.Y. Interactions between the Microbiota, Immune and Nervous Systems in Health and Disease. Nat. Neurosci. 2017, 20, 145–155. [CrossRef] [PubMed]
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
